Want to see ES:FAE full AI Analyst Report?
FAE Stock Chart & Stats
€4.60
-€0.01(-0.22%)
At close: 4:00 PM EDT
€4.60
-€0.01(-0.22%)
Day’s Range― - ―
52-Week Range€4.10 - €5.44
Previous CloseN/A
Volume9.99K
Average Volume (3M)130.56K
Market Cap
€1.41B
Enterprise Value€1.70K
Total Cash (Recent Filing)€136.78M
Total Debt (Recent Filing)€396.85M
Price to Earnings (P/E)10.4
Beta0.47
Next Earnings
Oct 29, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield4.98%
Share Statistics
EPS (TTM)0.43
Shares Outstanding316,223,940
10 Day Avg. Volume112,243
30 Day Avg. Volume130,562
Financial Highlights & Ratios
PEG Ratio-0.71
Price to Book (P/B)2.16
Price to Sales (P/S)2.63
P/FCF Ratio25.74
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.32
Revenue Forecast (FY)€758.51M
Bulls Say, Bears Say
Bulls Say
Vertically Integrated Business ModelFaes Farma’s vertical integration across R&D, manufacturing and commercialization plus exposure to human health, animal health and industrial supply creates durable operational flexibility. Owning manufacturing lowers reliance on third parties, supports gross margins, and enables long-term control of supply and product timing.
Historically Strong Profitability And Equity BaseBetween 2020–2024 Faes Farma delivered high gross and net margins and steady revenue growth, building a sizable equity cushion. That historical earnings power and equity base provide resilience to absorb shocks, support investment and dividends, and underpins longer-term creditworthiness versus peers.
Generally Positive Cash Generation Track RecordThe company has typically generated positive operating and free cash flow, enabling reinvestment, working capital and shareholder distributions. While volatile at times, this pattern indicates underlying cash-generative product lines and industrial cash conversion capacity that support near-term funding needs and strategic options.
Bears Say
2025 Revenue And Margin DeteriorationA clear step-down in 2025 (declining revenue and sharply compressed margins) signals execution or demand issues that can persist beyond a single quarter. Reduced top-line and margin pressure erodes operating leverage, weakens cash flow and may force reprioritization of R&D or commercial investments, raising medium-term growth risk.
Material Increase In LeverageFaes Farma’s shift from historically conservative leverage to a materially higher debt-to-equity (~0.55) reduces financial flexibility. Elevated leverage increases interest and refinancing risk, constrains balance-sheet capacity for M&A or capex, and heightens vulnerability to further margin or cash-flow setbacks.
Weaker Cash Conversion And FCF VolatilityOperating cash flow materially lagging net income and a 20.6% fall in free cash flow reflect weakening cash conversion and volatility (including a 2023 negative FCF). Persistent cash conversion weakness can limit dividend and reinvestment capacity, increase reliance on debt, and constrain strategic flexibility over the medium term.
Faes Farma News
FAE FAQ
What was Faes Farma SA’s price range in the past 12 months?
Faes Farma SA lowest stock price was €4.10 and its highest was €5.44 in the past 12 months.
What is Faes Farma SA’s market cap?
Faes Farma SA’s market cap is €1.41B.
When is Faes Farma SA’s upcoming earnings report date?
Faes Farma SA’s upcoming earnings report date is Oct 29, 2026 which is in 78 days.
How were Faes Farma SA’s earnings last quarter?
Faes Farma SA released its earnings results on Jul 30, 2026. The company reported €0.183 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Faes Farma SA overvalued?
According to Wall Street analysts Faes Farma SA’s price is currently Overvalued.
Does Faes Farma SA pay dividends?
Faes Farma SA pays a Semiannually dividend of €0.087 which represents an annual dividend yield of 4.98%. See more information on Faes Farma SA dividends here
What is Faes Farma SA’s EPS estimate?
Faes Farma SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Faes Farma SA have?
Faes Farma SA has 316,223,940 shares outstanding.
What happened to Faes Farma SA’s price movement after its last earnings report?
Faes Farma SA reported an EPS of €0.183 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.371%.
Which hedge fund is a major shareholder of Faes Farma SA?
Currently, no hedge funds are holding shares in ES:FAE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Faes Farma Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
37.24%
12-Months-Change
Fundamentals
Return on Equity
4.98%
Trailing 12-Months
Asset Growth
44.17%
Trailing 12-Months
Company Description
Faes Farma SA
Faes Farma, S.A. is a pharmaceutical enterprise dedicated to the research, development, manufacture, and distribution of both finished medicinal products and crucial raw materials. Its extensive operations span Spain and a multitude of international markets. The company's comprehensive product line encompasses prescription drugs, generic alternatives, over-the-counter (OTC) remedies, nutritional supplements, infant formula, and various other health-related items. Among its diverse offerings are Actimag (a magnesium pidolate), the anti-allergic Bilaxten, the anti-infective Bronquidiazina CR, Claversal for ulcerative colitis and Crohn's disease, the corticoid Dezacor, the anti-inflammatory Dolotren (also available as Dolotren Gel), Dynamogen (an anti-anorexic), Ferroprotina (an anti-anaemic), Hidroferol, Lipofen, Positon for dermatological conditions, strength-enhancing products such as Potenciator and Surmenalit, the laxative Pruina, the muscle relaxant and analgesic Robaxisal Compuesto, Trausan (a citicoline-based product), the venous vasoprotector Venosmil (and Venosmil Gel), and the anti-influenza medication Yendol. Furthermore, Faes Farma provides key active pharmaceutical ingredients, including Bilastine (an antihistamine molecule for allergic rhinitis, conjunctivitis, and urticaria), Calcifediol for bone metabolism, Deflazacort for treating osteoarticular diseases, Hidrosmin for venous insufficiency, and Mesalazine for digestive problems. The firm also engages in significant export activities. Founded in 1933, Faes Farma, S.A. is headquartered in Leioa, Spain.
Technical Analysis
Almirall
―
Grifols
―
LABORATORIO REIG JOFRE
―
Compania de Distribucion Integral Logista Holdings
―
Naturhouse Health
―